Protein methyltransferase inhibitors as personalized cancer therapeutics

被引：0

作者：

Copeland, Robert A. ^{[1
]}

机构：

[1] Epizyme Inc, Cambridge, MA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期

关键词：

D O I：

10.1158/1535-7163.TARG-13-PL03-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PL03-04

引用

页数：1

共 50 条

[1] Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics
Copeland, Robert A.
[J]. ONCOLOGIST, 2013, 18 : S2 - S2
[2] Protein methyltransferase inhibitors as personalized cancer therapeutics
Copeland, Robert
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[3] Protein methyltransferase inhibitors as personalized cancer therapeutics
Copeland, R.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[4] Protein Methyltransferase Inhibitors as Cancer Therapeutics
Copeland, Robert
[J]. FASEB JOURNAL, 2015, 29
[5] Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery
Copeland, Robert A.
[J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2018, 373 (1748)
[6] Oligonucleotide inhibitors of DNA methyltransferase for cancer therapeutics.
Sufrin, JR
Brank, A
Marasco, C
Christman, JK
[J]. CLINICAL CANCER RESEARCH, 1999, 5 : 3788S - 3788S
[7] Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
Copeland, R. A.
Moyer, M. P.
Richon, V. M.
[J]. ONCOGENE, 2013, 32 (08) : 939 - 946
[8] Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
R A Copeland
M P Moyer
V M Richon
[J]. Oncogene, 2013, 32 : 939 - 946
[9] Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors
Guccione, Ernesto
Schwarz, Megan
Di Tullio, Federico
Mzoughi, Slim
[J]. CURRENT OPINION IN PHARMACOLOGY, 2021, 59 : 33 - 42
[10] Personalized cancer diagnostics and therapeutics
Roukos, Dimitrios H.
[J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2009, 9 (03) : 227 - 229

← 1 2 3 4 5 →